Logo image of TNDM

TANDEM DIABETES CARE INC (TNDM) Stock Fundamental Analysis

USA - NASDAQ:TNDM - US8753722037 - Common Stock

15.73 USD
+0.94 (+6.36%)
Last: 10/20/2025, 1:54:09 PM
Fundamental Rating

3

TNDM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. TNDM has a bad profitability rating. Also its financial health evaluation is rather negative. TNDM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TNDM has reported negative net income.
TNDM had a positive operating cash flow in the past year.
In the past 5 years TNDM reported 4 times negative net income.
TNDM had a positive operating cash flow in 4 of the past 5 years.
TNDM Yearly Net Income VS EBIT VS OCF VS FCFTNDM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

TNDM has a Return On Assets of -23.46%. This is comparable to the rest of the industry: TNDM outperforms 48.42% of its industry peers.
With a Return On Equity value of -154.15%, TNDM is not doing good in the industry: 67.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -23.46%
ROE -154.15%
ROIC N/A
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
TNDM Yearly ROA, ROE, ROICTNDM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

TNDM has a Gross Margin of 52.55%. This is comparable to the rest of the industry: TNDM outperforms 46.32% of its industry peers.
In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
TNDM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
TNDM Yearly Profit, Operating, Gross MarginsTNDM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNDM has been increased compared to 1 year ago.
TNDM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TNDM is higher compared to a year ago.
TNDM Yearly Shares OutstandingTNDM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TNDM Yearly Total Debt VS Total AssetsTNDM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.13, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.13, TNDM is in line with its industry, outperforming 44.21% of the companies in the same industry.
A Debt/Equity ratio of 2.32 is on the high side and indicates that TNDM has dependencies on debt financing.
TNDM has a worse Debt to Equity ratio (2.32) than 84.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.32
Debt/FCF N/A
Altman-Z 0.13
ROIC/WACCN/A
WACC6.76%
TNDM Yearly LT Debt VS Equity VS FCFTNDM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.44 indicates that TNDM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.44, TNDM is in line with its industry, outperforming 48.95% of the companies in the same industry.
A Quick Ratio of 1.88 indicates that TNDM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.88, TNDM is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 1.88
TNDM Yearly Current Assets VS Current LiabilitesTNDM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

TNDM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.68%, which is quite good.
The Revenue has grown by 25.85% in the past year. This is a very strong growth!
TNDM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.01% yearly.
EPS 1Y (TTM)15.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.83%
Revenue 1Y (TTM)25.85%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%8.46%

3.2 Future

Based on estimates for the next years, TNDM will show a very strong growth in Earnings Per Share. The EPS will grow by 21.31% on average per year.
The Revenue is expected to grow by 9.26% on average over the next years. This is quite good.
EPS Next Y-49.18%
EPS Next 2Y18.78%
EPS Next 3Y23.44%
EPS Next 5Y21.31%
Revenue Next Year9.78%
Revenue Next 2Y9.75%
Revenue Next 3Y9.31%
Revenue Next 5Y9.26%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TNDM Yearly Revenue VS EstimatesTNDM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TNDM Yearly EPS VS EstimatesTNDM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNDM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNDM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNDM Price Earnings VS Forward Price EarningsTNDM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNDM Per share dataTNDM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

TNDM's earnings are expected to grow with 23.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.78%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

TNDM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANDEM DIABETES CARE INC

NASDAQ:TNDM (10/20/2025, 1:54:09 PM)

15.73

+0.94 (+6.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners121.11%
Inst Owner Change0.08%
Ins Owners0.7%
Ins Owner Change20.61%
Market Cap1.06B
Analysts71.72
Price Target21.71 (38.02%)
Short Float %11.87%
Short Ratio3.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.17%
Min EPS beat(2)-18.66%
Max EPS beat(2)-5.69%
EPS beat(4)2
Avg EPS beat(4)23.82%
Min EPS beat(4)-18.66%
Max EPS beat(4)104.27%
EPS beat(8)4
Avg EPS beat(8)14.08%
EPS beat(12)4
Avg EPS beat(12)-77.34%
EPS beat(16)5
Avg EPS beat(16)-126.63%
Revenue beat(2)1
Avg Revenue beat(2)1.64%
Min Revenue beat(2)-1.1%
Max Revenue beat(2)4.37%
Revenue beat(4)3
Avg Revenue beat(4)5.05%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)9.97%
Revenue beat(8)5
Avg Revenue beat(8)3.1%
Revenue beat(12)5
Avg Revenue beat(12)1.24%
Revenue beat(16)8
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-39.68%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)-23.18%
EPS NY rev (1m)-1.41%
EPS NY rev (3m)-50.67%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.06
P/FCF N/A
P/OCF 109.33
P/B 7.97
P/tB 7.97
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)0.14
OCFY0.91%
SpS14.82
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.46%
ROE -154.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.55%
FCFM N/A
ROA(3y)-14.09%
ROA(5y)-9.07%
ROE(3y)-42.99%
ROE(5y)-26.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-0.58%
F-Score5
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 2.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 372.84%
Cap/Sales 6.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 1.88
Altman-Z 0.13
F-Score5
WACC6.76%
ROIC/WACCN/A
Cap/Depr(3y)341.43%
Cap/Depr(5y)300.44%
Cap/Sales(3y)6.42%
Cap/Sales(5y)5.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.83%
EPS Next Y-49.18%
EPS Next 2Y18.78%
EPS Next 3Y23.44%
EPS Next 5Y21.31%
Revenue 1Y (TTM)25.85%
Revenue growth 3Y10.19%
Revenue growth 5Y21.01%
Sales Q2Q%8.46%
Revenue Next Year9.78%
Revenue Next 2Y9.75%
Revenue Next 3Y9.31%
Revenue Next 5Y9.26%
EBIT growth 1Y33.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.52%
EBIT Next 3Y43.44%
EBIT Next 5Y30.41%
FCF growth 1Y-31.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.96%
OCF growth 3Y-39.87%
OCF growth 5Y-10.38%